/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.02%
Natural Gas
-6.69%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.02%
VIX
N/A
Economic Calendar
EUR/USD
+0.02%
Natural Gas
-6.69%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+0.02%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Crude Inventories Fall By 6.4 Million Barrels
about 13 hours ago
Durable Goods Orders Exceed Market Expectations; Core Orders Miss
about 12 hours ago
German Ifo Business Climate Index Rises to 89.4 in April
about 19 hours ago
Tesla Faces Steepest Revenue Drop Since 2012 Amid Market Challenges
1 day ago
Composite PMI Drops To 50.9, Missing Analyst Expectations
1 day ago
German Services PMI Rises to a 10-Month High 53.3 in April
2 days ago
XRP News Today: SEC vs. Ripple Lawsuit Filings Spark Investor Jitters
about 3 hours ago
USD/JPY Forecast: BoJ’s Dilemma and US GDP Data on the Radar
about 4 hours ago
AUD to USD Forecast: RBA’s Next Move Amid US GDP Release
about 4 hours ago
Hedera (HBAR) Price Predicted to Hit $0.2 after Blackrock Announcement
about 5 hours ago
Hang Seng Index, Nikkei 225, ASX 200: Nikkei Futures Down 380 on Intervention Threats
about 5 hours ago
Here’s How Shiba Inu (SHIB) Price Could React to Latest $12M Fundraise
about 5 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
CPRX
profile
Catalyst Pharmaceuticals Inc
Follow
CPRX
(
Nasdaq - US
)
N/A
15.12
+0.39 (+2.65%)
in
:
usd
•
As of: Apr 24, 2024 15:59
UTC -4
Open
14.84
High
15.18
Low
14.78
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Catalyst Pharmaceuticals Inc
CEO
Richard J. Daly
Headquarters
355 alhambra circle,suite 801
coral gables, fl 33134, united states
Auditor
GRANT THORNTON LLP
Employees
167
Share Holders
17
Website
www.catalystpharma.com
Industry
pharmaceuticals major
Sector
health technology
Company Overview
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Catalyst Pharmaceuticals Inc
Statistics
Valuation Measures
Market Capitalization
2
1.78B
Enterprise Value
1.65B
Enterprise Value/EBITDA
(ttm)
13.76
Price to Earnings Ratio
(ttm)
18.42
Price to Book
(mrq)
4.58
Price to Sales
(ttm)
4.48
Price to Cash
(ytd)
7.34
Profitability
Gross Margin
(ttm)
87.04%
Operating Margin
(ttm)
24.10%
Profit Margin
(ttm)
18.53%
Return on Equity
(ttm)
26.56%
Return on Invested Capital
(ttm)
19.08%
Return on Assets
(ttm)
22.13%
Income Statement
Revenue
(ttm)
398.20M
Revenue Per Share
(ttm)
3.38
Gross Profit
(ttm)
346.24M
EBITDA
(ttm)
3
119.69M
Net Income Avi to Common
(ttm)
71.41M
Diluted EPS
(ttm)
0.61
Share Statistics
Beta (5Y Monthly)
0.89
52-Week Change
-8.47%
S&P500 52-Week Change
22.59%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
117.86M
Dividend Yield
0.00%
Float
4
103.73M
%
Held by Insiders
12.10%
%
Held by Institutions
79.22%
Balance Sheet
Total Cash
(mrq)
137.64M
Total Cash Per Share
(mrq)
1.17
Total Debt
(mrq)
0.00
Total Debt/Equity
(mrq)
0.00%
Current Ratio
(mrq)
2.88%
Quick Ratio
(mrq)
2.68%
Book Value Per Share
(mrq)
3.62
Cash Flow
Operating Cash Flow Per Share
(ytd)
1.26
Free Cash Flow
(ytd)
143.37M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker